Glox Therapeutics
Developing engineered protein bacteriocins as precision antibiotics against drug-resistant bacteria.
- Biotech & Life Sciences
- Seed
- Glasgow
- Sector
- Biotech & Life Sciences
- Stage
- Seed
- Based in
- Glasgow
- Founded
- 2023
- Funding raised
- £4.3M
- Website
- gloxtherapeutics.com
Glox Therapeutics is a spin-out from the Universities of Glasgow and Oxford working on precision antibiotics for antimicrobial resistance. Its discovery platform engineers protein bacteriocins, molecules that bacteria naturally use to kill closely related strains, into narrow-spectrum therapeutics. The lead programmes target Gram-negative pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae, which cause serious hospital infections with high mortality and limited treatment options. Founded in February 2023, the company is registered in Glasgow and runs laboratory work in Glasgow and Oxford. Its seed round was led by the Boehringer Ingelheim Venture Fund and Scottish Enterprise.
More startups in the directory
Boone
Nutrition app that analyses meals from photos, barcodes and receipts, with optional DNA insights.
Vocavio
AI voice analytics that measure team communication performance in high-pressure training.
KIT-AR
Augmented reality and AI software that guides manufacturing workers to cut assembly errors and quality costs.
Entropyst
Electrified reactor technology that converts methane and ammonia into clean hydrogen and carbon materials.
InfraFund
Platform for tokenised investment in renewable energy projects, letting communities co-own local clean energy.
UGiftMe
Online platform for buying and sending digital gift cards and vouchers from 1,000+ brands, with a wallet to swap them.
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.